Dose delay for grade 2 irAE

Vantrexa · Metastatic NSCLC

MI-2026-0396RoutineClosedWithin SLA

RARachel AdeyemiMSL, Oncology (UK & Ireland)

Received: 27 Aug 2026, 15:30 UTC
Channel: Web portal
Requestor type: HCP
Country / region / team: United States · North America · MI Americas
Category: Dosing
Response type: Standard response
Owner: RARachel Adeyemi
Due: 01 Sept 2026, 15:30 UTC
Responded: 29 Aug 2026, 05:30 UTC
Quality review: Not required
Related insight: —
Related standard response: SR-VTX-004 · Dose delay for grade 2 immune-related adverse events (v2)

Workflow

12-stage inquiry workflow (PRD §16). Advancing records an audit event.

Current stageClosedDemo action — not persisted

Routine: 120 h target · Routine 120 h / Urgent 48 h / Critical 24 h

SLA hours

120

Elapsed

38 h

to response

Remaining

82 h

32%

01 Sept 2026, 15:30 UTC
SLA due (120 h)
27 Aug 2026, 15:30 UTC
Received via Web portal
HCP · United States
27 Aug 2026, 15:30 UTC
Triage and assignment
Urgency Routine · assigned to MI Americas
29 Aug 2026, 05:30 UTC
Response sent
Standard response · quality review not required

Demo — drafts are not persisted

AI suggestion available for non-safety inquiries

Draft response

No audit events for this record

Create, update, approve and export events appear here with user, timestamp, previous and new values.

Data lineage: MI inquiry platform (IRMS, INT-05) · received 27 Aug 2026 · hourly sync.